The Manufacturers Life Insurance Company Acquires New Position in Merit Medical Systems, Inc. $MMSI

The Manufacturers Life Insurance Company acquired a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 484,435 shares of the medical instruments supplier’s stock, valued at approximately $33,591,000.

Other large investors have also modified their holdings of the company. Kilter Group LLC acquired a new stake in shares of Merit Medical Systems in the 2nd quarter valued at approximately $25,000. Los Angeles Capital Management LLC purchased a new position in Merit Medical Systems in the fourth quarter worth $25,000. Torren Management LLC acquired a new stake in Merit Medical Systems in the fourth quarter valued at $38,000. Covestor Ltd boosted its position in shares of Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares in the last quarter. Finally, Danske Bank A S acquired a new position in shares of Merit Medical Systems during the 3rd quarter worth $42,000. 99.66% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth.
• Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion.
• Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering.
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact.
• Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short.

Merit Medical Systems Price Performance

Shares of Merit Medical Systems stock opened at $90.54 on Thursday. The business’s fifty day moving average price is $78.85 and its 200 day moving average price is $72.74. Merit Medical Systems, Inc. has a twelve month low of $59.74 and a twelve month high of $94.75. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $5.41 billion, a P/E ratio of 37.41, a PEG ratio of 2.27 and a beta of 0.49.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The firm had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. During the same period in the previous year, the company posted $1.01 earnings per share. Merit Medical Systems’s revenue was up 9.5% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, research analysts anticipate that Merit Medical Systems, Inc. will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MMSI shares. JPMorgan Chase & Co. lifted their price objective on Merit Medical Systems from $77.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Needham & Company LLC boosted their price target on Merit Medical Systems from $90.00 to $101.00 and gave the company a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group increased their price target on Merit Medical Systems from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Piper Sandler raised their price objective on Merit Medical Systems from $96.00 to $106.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Robert W. Baird set a $98.00 target price on Merit Medical Systems in a research report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus price target of $100.00.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.